These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 24372680)

  • 1. Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside.
    Cuenca-Estrella M
    Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():54-9. PubMed ID: 24372680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
    Fera MT; La Camera E; De Sarro A
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antifungal agents in the treatment of systemic infections: Relevance of mechanism of action, activity profile and resistances].
    Cuenca-Estrella M
    Rev Esp Quimioter; 2010 Dec; 23(4):169-76. PubMed ID: 21191554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical relevance of mechanisms of antifungal drug resistance in filamentous fungi].
    Mellado E; Cuenca-Estrella M; Rodríguez-Tudela JL
    Enferm Infecc Microbiol Clin; 2002 Dec; 20(10):523-29; quiz 530, 539. PubMed ID: 12433354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mechanisms of resistance to antifungal agents].
    Makimura K
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():466-70. PubMed ID: 17455664
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.
    Yamazaki T; Inagaki Y; Fujii T; Ohwada J; Tsukazaki M; Umeda I; Kobayashi K; Shimma N; Page MG; Arisawa M
    Int J Antimicrob Agents; 2010 Oct; 36(4):324-31. PubMed ID: 20674282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal drug resistance mechanisms.
    Pemán J; Cantón E; Espinel-Ingroff A
    Expert Rev Anti Infect Ther; 2009 May; 7(4):453-60. PubMed ID: 19400764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reliability of the WIDERYST susceptibility testing system for detection of in vitro antifungal resistance in yeasts.
    Cuenca-Estrella M; Gomez-Lopez A; Gutierrez MO; Buitrago MJ; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1062-5. PubMed ID: 18195057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining the frontiers between antifungal resistance, tolerance and the concept of persistence.
    Delarze E; Sanglard D
    Drug Resist Updat; 2015 Nov; 23():12-19. PubMed ID: 26690338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of Mexican isolates of yeasts and moulds to amphotericin B and triazole antifungals.
    Arredondo-García JL; Amábile-Cuevas CF;
    J Infect Dev Ctries; 2009 Jun; 3(5):398-401. PubMed ID: 19759511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal drug resistance in pathogenic fungi.
    Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
    Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of antifungal resistance and its impact on clinical practice.
    Alcazar-Fuoli L; Mellado E
    Br J Haematol; 2014 Aug; 166(4):471-84. PubMed ID: 24749533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside.
    Beardsley J; Halliday CL; Chen SC; Sorrell TC
    Future Microbiol; 2018 Aug; 13(10):1175-1191. PubMed ID: 30113223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
    Panizo MM; Reviákina V; Dolande M; Selgrad S
    Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009).
    Pfaller MA; Castanheira M; Messer SA; Moet GJ; Jones RN
    Diagn Microbiol Infect Dis; 2011 Jan; 69(1):45-50. PubMed ID: 21146713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal resistance: why are we losing this battle?
    Paiva Macedo J; Dias VC
    Future Microbiol; 2024; 19(11):1027-1040. PubMed ID: 38904325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genesis of Azole Antifungal Resistance from Agriculture to Clinical Settings.
    Azevedo MM; Faria-Ramos I; Cruz LC; Pina-Vaz C; Rodrigues AG
    J Agric Food Chem; 2015 Sep; 63(34):7463-8. PubMed ID: 26289797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of in vitro antifungal susceptibility testing.
    Espinel-Ingroff A
    Rev Esp Quimioter; 2000 Jun; 13(2):161-6. PubMed ID: 10918088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.